Boehringer Ingelheim has launched an up-to-$7.358 billion-plus collaboration with Sino Biopharmaceutical (SBP Group) to develop next-generation cancer therapies based on antibody-drug conjugate (ADC) and T-cell engager (TcE) technologies. The companies signed a strategic multi-program option and license agreement to deepen their existing partnership in oncology, which includes three Boehringer-developed cancer treatments initiated in 2024.
The collaboration will encompass six biologic preclinical programs. Five programs will focus on treatments from SBP Group subsidiary LaNova Medicines, while the sixth comes from another subsidiary, Beijing Tide Pharmaceutical. SBP Group will oversee early development, and Boehringer Ingelheim may exercise options for exclusive development, manufacturing, and commercialization rights after clinical milestones are reached.
Boehringer Ingelheim will pay SBP Group upfront and near-term payments totaling $358 million, with up to $7 billion tied to achieving various milestones. This partnership is part of Boehringer Ingelheim’s strategy to build a broad oncology portfolio. Investors responded positively, sending SBP Group shares up 5% on the Hong Kong Stock Exchange.
Source: genengnews.com · Image: Chemical laboratory at the central cancer research labs by Unknown photographer, Public domain, via Wikimedia Commons
Use the database as your supply chain compass →
